JP2020533382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533382A5 JP2020533382A5 JP2020515147A JP2020515147A JP2020533382A5 JP 2020533382 A5 JP2020533382 A5 JP 2020533382A5 JP 2020515147 A JP2020515147 A JP 2020515147A JP 2020515147 A JP2020515147 A JP 2020515147A JP 2020533382 A5 JP2020533382 A5 JP 2020533382A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence identity
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 229940000425 combination drug Drugs 0.000 claims 9
- 102000025171 antigen binding proteins Human genes 0.000 claims 7
- 108091000831 antigen binding proteins Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 4
- 239000003207 proteasome inhibitor Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960002438 carfilzomib Drugs 0.000 claims 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 1
- 108010021331 carfilzomib Proteins 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003648 ixazomib Drugs 0.000 claims 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023120187A JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
| JP2025093685A JP2025131722A (ja) | 2017-09-14 | 2025-06-04 | 癌の組合せ治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558575P | 2017-09-14 | 2017-09-14 | |
| US62/558,575 | 2017-09-14 | ||
| PCT/IB2018/056967 WO2019053611A1 (en) | 2017-09-14 | 2018-09-12 | POLY THERAPY FOR THE TREATMENT OF CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120187A Division JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533382A JP2020533382A (ja) | 2020-11-19 |
| JP2020533382A5 true JP2020533382A5 (enExample) | 2021-10-21 |
Family
ID=63713944
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515147A Pending JP2020533382A (ja) | 2017-09-14 | 2018-09-12 | 癌の組合せ治療 |
| JP2023120187A Pending JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
| JP2025093685A Pending JP2025131722A (ja) | 2017-09-14 | 2025-06-04 | 癌の組合せ治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120187A Pending JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
| JP2025093685A Pending JP2025131722A (ja) | 2017-09-14 | 2025-06-04 | 癌の組合せ治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11401334B2 (enExample) |
| EP (1) | EP3694878A1 (enExample) |
| JP (3) | JP2020533382A (enExample) |
| CN (1) | CN111108125A (enExample) |
| BR (1) | BR112020005079A2 (enExample) |
| CA (1) | CA3075714A1 (enExample) |
| WO (1) | WO2019053611A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| PH12021552986A1 (en) * | 2019-05-31 | 2023-08-14 | Dana Farber Cancer Inst Inc | Combination therapy |
| EP4085076A4 (en) | 2020-01-03 | 2024-01-24 | Biosion, Inc. | BCMA-BINDING ANTIBODIES AND USES THEREOF |
| CA3210069A1 (en) * | 2021-03-03 | 2022-09-09 | Tong Zhu | Antibody-drug conjugates comprising an anti-bcma antibody |
| CN118591560A (zh) * | 2022-01-25 | 2024-09-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 癌症的组合疗法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| EP2251344B2 (en) | 2001-01-25 | 2024-04-24 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Formulation of boronic acid compounds |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| CA2562411A1 (en) | 2004-04-15 | 2005-11-10 | Proteolix, Inc. | Compounds for enzyme inhibition |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| ES2408216T3 (es) | 2004-12-07 | 2013-06-19 | Onyx Therapeutics, Inc. | Composición para la inhibición del proteasoma |
| US7687456B2 (en) | 2005-11-09 | 2010-03-30 | Proteolix, Inc. | Compounds for enzyme inhibition |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| BR122014008753A2 (pt) | 2008-06-17 | 2015-12-29 | Millennium Pharm Inc | compostos de éster boronato e composições farmacêuticas dos mesmos |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
| PH12013502421A1 (en) | 2011-05-27 | 2014-01-06 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| UA112434C2 (uk) * | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
| KR20160033795A (ko) | 2012-02-28 | 2016-03-28 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| UY35091A (es) | 2012-10-24 | 2014-05-30 | Onyx Therapeutics Inc | Formulaciones de liberacion modificada para oprozomib |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| PL2953972T3 (pl) | 2013-02-05 | 2021-03-08 | Engmab Sàrl | Metoda wyboru przeciwciał przeciwko bcma |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| JP6285274B2 (ja) | 2014-04-28 | 2018-02-28 | 株式会社ブリヂストン | バイアスタイヤ及びその製造方法 |
| GB201409471D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| SG10201900455YA (en) | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| CN106573042A (zh) * | 2014-08-05 | 2017-04-19 | 埃克塞里艾克西斯公司 | 治疗多发性骨髓瘤的药物组合 |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| SG10201900931XA (en) | 2014-12-05 | 2019-02-27 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| DK3226897T3 (da) | 2014-12-05 | 2021-04-19 | Memorial Sloan Kettering Cancer Center | Antistoffer der rammer b-cellemodningsantigen og fremgangsmåder til anvendelse |
| ES3012402T3 (en) * | 2015-04-13 | 2025-04-09 | Pfizer | Therapeutic antibodies and their uses |
| PT3331910T (pt) | 2015-08-03 | 2020-03-24 | Engmab Sarl | Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano |
| EP3147954A1 (en) | 2015-09-22 | 2017-03-29 | Nokia Technologies Oy | Photodetector with conductive channel made from two dimensional material and its manufacturing method |
| EP4015537A1 (en) * | 2015-12-01 | 2022-06-22 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
-
2018
- 2018-09-12 WO PCT/IB2018/056967 patent/WO2019053611A1/en not_active Ceased
- 2018-09-12 CN CN201880060081.0A patent/CN111108125A/zh active Pending
- 2018-09-12 EP EP18779780.8A patent/EP3694878A1/en active Pending
- 2018-09-12 US US16/646,836 patent/US11401334B2/en active Active
- 2018-09-12 CA CA3075714A patent/CA3075714A1/en active Pending
- 2018-09-12 BR BR112020005079-2A patent/BR112020005079A2/pt unknown
- 2018-09-12 JP JP2020515147A patent/JP2020533382A/ja active Pending
-
2022
- 2022-06-22 US US17/846,950 patent/US12234293B2/en active Active
-
2023
- 2023-07-24 JP JP2023120187A patent/JP2023139178A/ja active Pending
-
2025
- 2025-01-22 US US19/033,609 patent/US20250163172A1/en active Pending
- 2025-06-04 JP JP2025093685A patent/JP2025131722A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533382A5 (enExample) | ||
| JP2020500538A5 (enExample) | ||
| JP2017528476A5 (enExample) | ||
| MX2025004236A (es) | Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana) | |
| JP2020508303A5 (enExample) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| JP2018507220A5 (enExample) | ||
| JP2024167313A5 (enExample) | ||
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| FI3740504T3 (fi) | CD70-yhdistelmähoito | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2020533383A5 (enExample) | ||
| JP2017534577A5 (enExample) | ||
| JP2018535650A5 (enExample) | ||
| JP2019504032A5 (enExample) | ||
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2018035138A5 (enExample) | ||
| RU2021103288A (ru) | МОЛЕКУЛЫ СО СПЕЦИФИЧНОСТЬЮ В ОТНОШЕНИИ CD79 и CD22 | |
| JP2017535257A5 (enExample) | ||
| JP2011528902A5 (enExample) | ||
| JP2013542194A5 (enExample) | ||
| ME02807B (me) | HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE | |
| JP2010516229A5 (enExample) | ||
| NZ623347A (en) | Novel anti-dr5 antibody |